Navigation Links
New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension

(Stanton, Jensen, Nussberger, O'Brien, Hypertension.2003; 42: 1137-1143).

About Speedel Speedel is a public biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead compound SPP100 ( Tekturna/Rasilez [10]), the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back to Novartis Pharma in 2002 for further development and commercialisation; Tekturna was approved by the FDA in the US in March 2007, and filed by Novartis with the EMEA in the EU in Q3 2006. Our pipeline covers three different modes of action, and in addition to SPP100, includes SPP301 in Phase III (on hold), SPP200 in Phase II, SPP635 in Phase Il, SPP1148 in Phase I and several pre-clinical projects.

Speedel develops novel product candidates through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing. Our team of approximately 70 employees, including over 30 experienced pharmaceutical scientists, is located at our headquarters and laboratories in Basel, Switzerland and at offices in New Jersey, USA and Tokyo, Japan.

In January 2007 the company raised gross proceeds of CHF 55.5 million (approximately EUR 34.3 million or USD 44.5 million) through a convertible bond issue. In March 2006 the company raised gross proceeds of CHF 83.95 million (approximately EUR 53m or USD 64m) through the public offering of 500,000 treasury shar
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:5/15/2008)...- Cytopia Limited,(ASX: CYT...ng oral,presentation on CYT997 at the 2008 Annual ...gy (ASCO) will be accessible to the public via ASC...ursday 15 May (US EDT)., The oral presentation, e...otoxic and vascular disrupting agent, in patients ...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)...- Tigris Pharmaceuticals,Inc. announ...and,Development Agreement (CRADA) with the Nationa...l and preclinical development of AFP-464, an,amino...is converted to,metabolites which bind covalently ..., This is part of a four-year CRADA encompassing ...
Breaking Medicine Technology:Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 1Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 3Pharsight Expands Global Consulting Services Teams 3640 1Pharsight Expands Global Consulting Services Teams 3640 2Pharsight Expands Global Consulting Services Teams 3640 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 1Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 4Study 3A Modafinil is effective in treating excessive sleepiness 3637 1Study 3A Modafinil is effective in treating excessive sleepiness 3637 2
... LONDON, June 28, 2007--A cervical cancer vaccine ...cancer and precancerous lesions,associated with th... vaccine, conclude authors of an Article published...cet., HPV types 16 and 18 account for 70% or more,...up to 15,oncogenic HPV types which can contribute ...
... Company to Proceed with Development Program for ...BRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alke... preliminary results from a,clinical trial of ALKS...results, the company plans to move forward with it...to treat alcohol,dependence. ALKS 29 is a combinat...
Other Medicine Technology:Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 4
(Date:5/16/2008)... LONDON, May 16 /PRNewswire/ -- Huntsworth plc (L...lic relations and healthcare communications,group ...gement report with,respect to the Group,s performa...arch 31, 2008)., The statement follows below., ...rth plc, Interim Management ...
(Date:5/16/2008)... Appeals for Funds Focus on Millions of Childre...-- The U.S. Fund for UNICEF and The,Advertising Co...and promote,a series of national public service an...ncluding Ben Stiller, Nicole Ritchie, Joel Madden,...igned to help survivors of the,Myanmar cyclone. Th...
(Date:5/16/2008)... LARGO, Fla., May 16 /PRNewswire/ -- ExamForce an...new Corporate and Government Sales Manager.,Mongeo...ion for (ISC)2,Americas where he oversaw governmen...edential, one of the top security certifications i...ater, Florida, recently left (ISC)2,Americas to sp...
(Date:5/16/2008)...eatment guidelines quickly disseminated to communi...ay 16 (HealthDay News) -- Partnerships between maj... are a quick and effective way to spread cancer tr...cer Center in Philadelphia. , Most new cancer t...d most cancer care is provided at community hospit...
Breaking Medicine News(10 mins):Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:Partnerships Effective Communicators of Cancer Advances 2
...onducted by an international team of researchers i...rn Cameroon. The researchers analyzed the feces sa...rest floors in Africa. They collected 599 fecal sa...imian immunodeficiency virus which affects the chi...
...died of heat and hundreds of people suffering from...n Pakistan's central Punjab province// , Daily Tim...ren have died of the disease, the newspaper said. ...ported from southern Punjab, as temperatures shot ...
...lding AG (RHHBY), a Swiss pharmaceutical company s...eptin was added to hormonal therapy//. When the pa...ell as HER2-positive, this combined therapy proves...ve breast cancer results lower risk rate whereas H...
...of motorist has resulted in over 4,000 people dyin...in the last three years// , said a senior Delhi Po...ound 1,500 sq km and it is difficult to control an...rd of driving is not up to the mark," Qamar Ahmed,...
Other Medicine News:Health News:Road Traffic Accidents Kill 4,000 people in Delhi 2
Millar Mikro-Tip pressure intravascular catheters provide a simple, efficient and highly accurate method of measuring pressures in the heart or cardiovascular system. These reusable, thromboresistant
These dual pressure sensor catheters incorporate a lumen for sampling/slow-speed injection, slow-speed injection/guide wire, or high-speed injection/guide wire. The model SPC-784A for high-speed inje
...r Intravascular Mikro-Tip Pressure Catheters; Mill...e sensor catheters for simultaneous high fidelity ...e for measuring pressure gradients across a valve,...The catheters are made of Polyurethane material (s...
...a flat detector biplane angiography system with fl... diagnostics and intervention. The flexible and er...t the system configuration to focus on cardiologic...ns with tableside operation. ,AXIOM Artis dBC p...
Medicine Products: